MARK2 and breast cancer: It was observed that the top scoring network amongst the malignant mammary cancers have a central node of mitotic checkpoint serine/threonine kinase (BUB1B), while top network in the benign tumours have a central node of vascular endothelial growth factor (VEGF), as shown in Fig 13.